BIA
RVNC

Bell Investment Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bell Investment Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-126
Closed -$324 – 1960
2024
Q2 		$324 Buy
+126
New +$430 ﹤0.01% 1897
2021
Q4 		– Sell
-18
Closed -$1K – 1971
2021
Q3 		$1K Buy
+18
New +$514 ﹤0.01% 1635

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Bell Investment Advisors's RVNC Position: Q3 2024 in Review

Bell Investment Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 126 shares — an estimated $324 sold.

Bell Investment Advisors first reported a position in RVNC in Q3 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Bell Investment Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Bell Investment Advisors sold 126 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $324.
  • Bell Investment Advisors first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 2 quarters.
  • Bell Investment Advisors's Revance Therapeutics, Inc. position peaked at $1K in Q3 2021.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Bell Investment Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.